Preferred Label : Relatlimab;
NCIt synonyms : Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy
Chain), Disulfide with Human Light Chain, Dimer;
NCIt definition : A monoclonal antibody directed against the inhibitor receptor lymphocyte activation
gene-3 (LAG-3), with potential immunomodulating and antineoplastic activities. Upon
administration, relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs).
This may activate antigen-specific T-lymphocytes and enhance cytotoxic T cell-mediated
tumor cell lysis, which leads to a reduction in tumor growth. LAG-3 is a member of
the immunoglobulin superfamily (IgSF) and binds to major histocompatibility complex
(MHC) class II. LAG-3 expression on TILs is associated with tumor-mediated immune
suppression.;
UNII : AF75XOF6W3;
CAS number : 1673516-98-7;
Molecule name : BMS-986016; BMS 986016;
NCI Metathesaurus CUI : CL454288;
Origin ID : C111999;
UMLS CUI : C4724799;
Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
https://www.ema.europa.eu/en/medicines/human/EPAR/opdualag
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug combinations
Relatlimab
Relatlimab
Nivolumab
Nivolumab
Antineoplastic Agents, Immunological
nivolumab and relatlimab
melanoma
product surveillance, postmarketing
Advanced Cutaneous Melanoma
Metastatic Cutaneous Melanoma
Unresectable Cutaneous Melanoma
adolescent
adult
Immune Checkpoint Inhibitors
Immune Checkpoint Inhibitors
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
PD-L1 Expression Less than 1 Percent
infusions, intravenous
programmed cell death 1 receptor
receptors, immunologic
Lag3 protein, human
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
relatlimab
relatlimab
---
